Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Other financing activities (2018 - 2025)

Marker Therapeutics (MRKR) has disclosed Other financing activities for 9 consecutive years, with $111131.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 119.87% to $111131.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $537540.0 through Dec 2025, up 118.63% year-over-year, with the annual reading at $537540.0 for FY2025, 118.63% up from the prior year.
  • Other financing activities for Q4 2025 was $111131.0 at Marker Therapeutics, up from $33279.0 in the prior quarter.
  • The five-year high for Other financing activities was $1.7 million in Q2 2021, with the low at $13986.0 in Q2 2025.
  • Average Other financing activities over 5 years is $683733.0, with a median of $492011.5 recorded in 2023.
  • The sharpest move saw Other financing activities tumbled 89.65% in 2024, then surged 377.41% in 2025.
  • Over 5 years, Other financing activities stood at $1.5 million in 2021, then crashed by 51.11% to $717173.0 in 2022, then plummeted by 80.01% to $143370.0 in 2023, then crashed by 64.75% to $50544.0 in 2024, then soared by 119.87% to $111131.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $111131.0, $33279.0, and $13986.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.